Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Costanza, Mariantonia Dr. (1) Hinze, Christian Dr. med. Dipl.-Math. (1) Scheidereit, Claus Prof. Dr. (1) Sczakiel, Henrike (1) Wollert-Wulf, Brigitte (1) (-) Janz, Martin Dr. (7) (-) Mathas, Stephan Dr. (10) 1999 (1) 2000 (1) 2001 (1) 2002 (5) 2003 (3) 2004 (3) 2005 (3) 2006 (5) 2007 (4) 2008 (4) 2009 (4) 2010 (3) (-) 2011 (4) 2012 (2) 2013 (3) 2014 (2) (-) 2015 (5) 2016 (3) 2017 (5) (-) 2018 (1) 2019 (2) 2020 (6) 2021 (3) 2022 (7) 2024 (2) (-) Biology of Malignant Lymphomas (10) Immune Dysregulations in Oncology (1) Immune Regulation and Cancer (1) Molecular Immunology and Gene Therapy (12) Systems Biology of Gene Regulatory Elements (2) 10 Results: Active Filter: Janz, Martin Dr.Mathas, Stephan Dr.Biology of Malignant Lymphomas201120152018 Sort: Result score Newest to oldest Oldest to newest August 01, 2011 / J Exp Med Genomic loss of the putative tumor suppressor gene E2A in human lymphoma A. Steininger M. Moebs R. Ullmann K. Koechert S. Kreher B. Lamprecht I. Anagnostopoulos M. Hummel J. Richter M. Beyer M. Janz C.D. Klemke H. Stein B. Doerken W. Sterry E. Schrock S. Mathas C. Assaf April 14, 2011 / Oncogene High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas K. Koechert K. Ullrich S. Kreher J.C. Aster M. Kitagawa K. Joehrens I. Anagnostopoulos F. Jundt B. Lamprecht U. Zimber-Strobl H. Stein M. Janz B. Doerken S. Mathas July 14, 2011 / Oncogene Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells U.M. Fagerli K. Ullrich T. Stuehmer T. Holien K. Koechert R.U. Holt O. Bruland M. Chatterjee H. Nogai G. Lenz J.D. Shaughnessy S. Mathas A. Sundan R.C. Bargou B. Doerken M. Borset M. Janz November 01, 2011 / Br J Haematol BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines K. Ullrich K.D. Wurster B. Lamprecht K. Koechert A. Engert B. Doerken M. Janz S. Mathas May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas September 01, 2018 / Leukemia The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma N. Schleussner O. Merkel M. Costanza H.C. Liang F. Hummel C. Romagnani P. Durek I. Anagnostopoulos M. Hummel K. Jöhrens A. Niedobitek P.R. Griffin R. Piva H.L. Sczakiel W. Woessmann C. Damm-Welk C. Hinze D. Stoiber B. Gillissen S.D. Turner E. Kaergel L. von Hoff M. Grau G. Lenz B. Dörken C. Scheidereit L. Kenner M. Janz S. Mathas January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert June 01, 2015 / Front Biosci The origins of ALK translocations V. Roukos S. Mathas
August 01, 2011 / J Exp Med Genomic loss of the putative tumor suppressor gene E2A in human lymphoma A. Steininger M. Moebs R. Ullmann K. Koechert S. Kreher B. Lamprecht I. Anagnostopoulos M. Hummel J. Richter M. Beyer M. Janz C.D. Klemke H. Stein B. Doerken W. Sterry E. Schrock S. Mathas C. Assaf
April 14, 2011 / Oncogene High-level expression of Mastermind-like 2 contributes to aberrant activation of the NOTCH signaling pathway in human lymphomas K. Koechert K. Ullrich S. Kreher J.C. Aster M. Kitagawa K. Joehrens I. Anagnostopoulos F. Jundt B. Lamprecht U. Zimber-Strobl H. Stein M. Janz B. Doerken S. Mathas
July 14, 2011 / Oncogene Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells U.M. Fagerli K. Ullrich T. Stuehmer T. Holien K. Koechert R.U. Holt O. Bruland M. Chatterjee H. Nogai G. Lenz J.D. Shaughnessy S. Mathas A. Sundan R.C. Bargou B. Doerken M. Borset M. Janz
November 01, 2011 / Br J Haematol BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines K. Ullrich K.D. Wurster B. Lamprecht K. Koechert A. Engert B. Doerken M. Janz S. Mathas
May 01, 2015 / Leukemia The IL-15 cytokine system provides growth and survival signals in hodgkin lymphoma and enhances the inflammatory phenotype of HRS cells K. Ullrich F. Blumenthal-Barby B. Lamprecht K. Koechert D. Lenze M. Hummel S. Mathas B. Doerken M. Janz
March 01, 2015 / Cytokine Cytokine and proinflammatory gene expression in classical Hodgkin lymphoma: its more than NF-κB! S. Kreher P. Cauchy C. Bonifer S. Mathas
September 01, 2018 / Leukemia The AP-1-BATF and -BATF3 module is essential for growth, survival and TH17/ILC3 skewing of anaplastic large cell lymphoma N. Schleussner O. Merkel M. Costanza H.C. Liang F. Hummel C. Romagnani P. Durek I. Anagnostopoulos M. Hummel K. Jöhrens A. Niedobitek P.R. Griffin R. Piva H.L. Sczakiel W. Woessmann C. Damm-Welk C. Hinze D. Stoiber B. Gillissen S.D. Turner E. Kaergel L. von Hoff M. Grau G. Lenz B. Dörken C. Scheidereit L. Kenner M. Janz S. Mathas
January 01, 2015 / Blood Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma A. Weilemann M. Grau T. Erdmann O. Merkel U. Sobhiafshar I. Anagnostopoulos M. Hummel A. Siegert C. Hayford H. Madle B. Wollert-Wulf I. Fichtner B. Dörken S. Dirnhofer S. Mathas M. Janz N.C.T. Emre A. Rosenwald G. Ott P. Lenz A. Tzankov G. Lenz
April 11, 2015 / Lancet Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial K. Behringer H. Goergen F. Hitz J.M. Zijlstra R. Greil J. Markova S. Sasse M. Fuchs M.S. Topp M. Soekler S. Mathas J. Meissner M. Wilhelm P. Koch H.W. Lindemann E. Schalk R. Semrau J. Kriz T. Vieler M. Bentz E. Lange R. Mahlberg A. Hassler M. Vogelhuber D. Hahn J. Mezger S.W. Krause N. Skoetz B. Böll B. von Tresckow V. Diehl M. Hallek P. Borchmann H. Stein H. Eich A. Engert